DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer

被引:6
作者
Wang, Jieyu [1 ,2 ]
Li, Jun [1 ]
Chen, Ruifang [1 ]
Yue, Huiran [1 ]
Li, Wenzhi [1 ,2 ]
Wu, Beibei [1 ]
Bai, Yang [1 ]
Zhu, Guohua [1 ,2 ]
Lu, Xin [1 ,2 ]
机构
[1] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, 128 Shenyang Rd, Shanghai 200090, Peoples R China
[2] Fudan Univ, Shanghai Key Lab Female Reprod Endocrine Related, Shanghai, Peoples R China
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
Ovarian cancer; High-grade serous ovarian cancer; DNA profiling; Methylation subtypes; Prognosis; EXPRESSION; GENE; CLASSIFICATION; ASSOCIATION; RESISTANCE; SIGNATURES; METHYLOME; DIAGNOSIS; PATTERNS;
D O I
10.1186/s13148-021-01178-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-grade serous ovarian cancer (HGSOC) is the most common type of epigenetically heterogeneous ovarian cancer. Methylation typing has previously been used in many tumour types but not in HGSOC. Methylation typing in HGSOC may promote the development of personalized care. The present study used DNA methylation data from The Cancer Genome Atlas database and identified four unique methylation subtypes of HGSOC. With the poorest prognosis and high frequency of residual tumours, cluster 4 featured hypermethylation of a panel of genes, which indicates that demethylation agents may be tested in this group and that neoadjuvant chemotherapy may be used to reduce the possibility of residual lesions. Cluster 1 and cluster 2 were significantly associated with metastasis genes and metabolic disorders, respectively. Two feature CpG sites, cg24673765 and cg25574024, were obtained through Cox proportional hazards model analysis of the CpG sites. Based on the methylation level of the two CpG sites, the samples were classified into high- and low-risk groups to identify the prognostic information. Similar results were obtained in the validation set. Taken together, these results explain the epigenetic heterogeneity of HGSOC and provide guidance to clinicians for the prognosis of HGSOC based on DNA methylation sites.
引用
收藏
页数:12
相关论文
共 50 条
[21]   Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling [J].
Bashashati, Ali ;
Ha, Gavin ;
Tone, Alicia ;
Ding, Jiarui ;
Prentice, Leah M. ;
Roth, Andrew ;
Rosner, Jamie ;
Shumansky, Karey ;
Kalloger, Steve ;
Senz, Janine ;
Yang, Winnie ;
McConechy, Melissa ;
Melnyk, Nataliya ;
Anglesio, Michael ;
Luk, Margaret T. Y. ;
Tse, Kane ;
Zeng, Thomas ;
Moore, Richard ;
Zhao, Yongjun ;
Marra, Marco A. ;
Gilks, Blake ;
Yip, Stephen ;
Huntsman, David G. ;
McAlpine, Jessica N. ;
Shah, Sohrab P. .
JOURNAL OF PATHOLOGY, 2013, 231 (01) :21-34
[22]   The peritoneal tumour microenvironment of high-grade serous ovarian cancer [J].
Leinster, D. Andrew ;
Kulbe, Hagen ;
Everitt, Gemma ;
Thompson, Richard ;
Perretti, Mauro ;
Gavins, Felicity N. E. ;
Cooper, Dianne ;
Gould, David ;
Ennis, Darren P. ;
Lockley, Michelle ;
McNeish, Iain A. ;
Nourshargh, Sussan ;
Balkwill, Frances R. .
JOURNAL OF PATHOLOGY, 2012, 227 (02) :136-145
[23]   Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer [J].
Freimund, Alison E. ;
Beach, Jessica A. ;
Christie, Elizabeth L. ;
Bowtell, David D. L. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) :983-+
[24]   Identification of a four-gene methylation biomarker panel in high-grade serous ovarian carcinoma [J].
Baranova, Ivana ;
Kovarikova, Helena ;
Laco, Jan ;
Sedlakova, Iva ;
Vrbacky, Filip ;
Kovarik, Dalibor ;
Hejna, Petr ;
Palicka, Vladimir ;
Chmelarova, Marcela .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (08) :1332-1340
[25]   WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells [J].
Yu, Hai-Lan ;
Ma, Xu-Dong ;
Tong, Jin-Fei ;
Li, Jian-Qiong ;
Guan, Xiao-Jing ;
Yang, Jian-Hua .
ONCOTARGETS AND THERAPY, 2019, 12 :6191-6201
[26]   Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer [J].
Silva, Romina ;
Glennon, Kate ;
Metoudi, Michael ;
Moran, Bruce ;
Salta, Sofia ;
Slattery, Karen ;
Treacy, Ann ;
Martin, Terri ;
Shaw, Jacqui ;
Doran, Peter ;
Lynch, Lydia ;
Jeronimo, Carmen ;
Perry, Antoinette S. ;
Brennan, Donal J. .
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) :120-132
[27]   AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer [J].
Hojnik, Marko ;
Suster, Natasa Kenda ;
Smrkolj, Spela ;
Sisinger, Damjan ;
Grazio, Snjezana Frkovic ;
Verdenik, Ivan ;
Rizner, Tea Lanisnik .
CANCERS, 2022, 14 (03)
[28]   The Effect of WT-1 Positivity on Survival Outcomes in Patients with High-grade Serous Epithelial Ovarian Cancer [J].
Karakas, Sema ;
Tunca, Aysun Fendal ;
Altinay, Serdar ;
Yildiz, Gunes Ozlem ;
Ekin, Murat .
MEDICAL JOURNAL OF BAKIRKOY, 2022, 18 (02) :151-156
[29]   Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer [J].
Si, Manfei ;
Zhang, Junji ;
Cao, Jianzhong ;
Xie, Zhibo ;
Shu, Shan ;
Zhu, Yapei ;
Lang, Jinghe .
ONCOTARGETS AND THERAPY, 2019, 12 :10057-10075
[30]   Protein anabolism is key to long-term survival in high-grade serous ovarian cancer [J].
Wang, Lingxiang ;
Sun, Tao ;
Li, Shumei ;
Zhang, Zhengmao ;
Jia, Jingde ;
Shan, Baoen .
TRANSLATIONAL ONCOLOGY, 2021, 14 (01)